Literature DB >> 28403627

Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.

Maile Young Karris1.   

Abstract

Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF). Tenofovir alafenamide fumarate (TAF) is a novel prodrug with less nephrotoxicity. We report resolution of Fanconi syndrome in a HIV and hepatitis B coinfected patient switched from TDF to TAF.

Entities:  

Keywords:  Fanconi syndrome; HIV; hepatitis B; tenofovir alafenamide

Mesh：

Substances：

Year:  2017        PMID： 28403627      PMCID： PMC5512307          DOI： 10.1089/AID.2016.0180

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  11 in total

1.  Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

Authors:  Sonia Rodríguez-Nóvoa; Pablo Labarga; Antonio D'avolio; Pablo Barreiro; Marta Albalate; Eugenia Vispo; Carmen Solera; Marco Siccardi; Stefano Bonora; Giovanni Di Perri; Vincent Soriano
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

2.  Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.

Authors:  Martin Markowitz; Andrew Zolopa; Kathleen Squires; Peter Ruane; Dion Coakley; Brian Kearney; Lijie Zhong; Michael Wulfsohn; Michael D Miller; William A Lee
Journal:  J Antimicrob Chemother       Date:  2014-02-06       Impact factor: 5.790

3.  First case report of renal improvement on tenofovir alafenamide in an HIV/hepatitis B virus-coinfected patient with adefovir-induced Fanconi's syndrome.

Authors:  Magali Garcia; Gwenaël Le Moal; Cendrine Godet; Guillaume Beraud; Carine Chagneau-Derrode; France Roblot
Journal:  AIDS       Date:  2016-06-01       Impact factor: 4.177

4.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Authors:  Paul E Sax; David Wohl; Michael T Yin; Frank Post; Edwin DeJesus; Michael Saag; Anton Pozniak; Melanie Thompson; Daniel Podzamczer; Jean Michel Molina; Shinichi Oka; Ellen Koenig; Benoit Trottier; Jaime Andrade-Villanueva; Gordon Crofoot; Joseph M Custodio; Andrew Plummer; Lijie Zhong; Huyen Cao; Hal Martin; Christian Callebaut; Andrew K Cheng; Marshall W Fordyce; Scott McCallister
Journal:  Lancet       Date:  2015-04-15       Impact factor: 79.321

5.  Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities.

Authors:  Leal C Herlitz; Sumit Mohan; Michael B Stokes; Jai Radhakrishnan; Vivette D D'Agati; Glen S Markowitz
Journal:  Kidney Int       Date:  2010-09-01       Impact factor: 10.612

6.  Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection.

Authors:  David M Gracey; Paul Snelling; Paul McKenzie; Simone I Strasser
Journal:  Antivir Ther       Date:  2013-07-10

7.  Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.

Authors:  Theodora E M S de Vries-Sluijs; Jurriën G P Reijnders; Bettina E Hansen; Hans L Zaaijer; Jan M Prins; Suzan D Pas; Martin Schutten; Andy I M Hoepelman; Clemens Richter; Jan W Mulder; Rob A de Man; Harry L A Janssen; Marchina E van der Ende
Journal:  Gastroenterology       Date:  2010-08-26       Impact factor: 22.682

8.  Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.

Authors:  James M Mikula; Maura M Manion; Frank Maldarelli; Lucila M Suarez; Jaha F Norman-Wheeler; Alex G Ober; Robin L Dewar; Jeffrey B Kopp; H Clifford Lane; Alice K Pau
Journal:  Antivir Ther       Date:  2016-03-08

9.  Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Authors:  Anton Pozniak; Jose R Arribas; Joseph Gathe; Samir K Gupta; Frank A Post; Mark Bloch; Anchalee Avihingsanon; Gordon Crofoot; Paul Benson; Kenneth Lichtenstein; Moti Ramgopal; Ploenchan Chetchotisakd; Joseph M Custodio; Michael E Abram; Xuelian Wei; Andrew Cheng; Scott McCallister; Devi SenGupta; Marshall W Fordyce
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-15       Impact factor: 3.731

10.  Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Authors:  Frank A Post; Pablo Tebas; Amanda Clarke; Laurent Cotte; William R Short; Michael E Abram; Shuping Jiang; Andrew Cheng; Moupali Das; Marshall W Fordyce
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731
View more
  3 in total

1.  Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient.

Authors:  Nomvuyo Z Mothobi; Jeffrey Masters; Deborah J Marriott
Journal:  Ther Adv Infect Dis       Date:  2018-07-10

2.  Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity.

Authors:  Laura N Walti; Julia Steinrücken; Andri Rauch; Gilles Wandeler
Journal:  Open Forum Infect Dis       Date:  2018-10-24       Impact factor: 3.835

3.  Impact of Tenofovir Disoproxil-Induced Fanconi Syndrome on Bone Material Quality: A Case Report.

Authors:  Benjamin Hadzimuratovic; Judith Haschka; Markus A Hartmann; Stéphane Blouin; Nadja Fratzl-Zelman; Jochen Zwerina; Roland Kocijan
Journal:  JBMR Plus       Date:  2021-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.